Below copied from IHUB, Fletch falconer66a T
Post# of 1460
(Total Views: 731)
Posted On: 05/15/2019 8:57:07 AM
Below copied from IHUB,
Fletch
falconer66a Tuesday, 05/14/19 01:26:51 PM
Re: Bourbon_on_my_cornflakes post# 192761 0
Post # of 192830
Production Cost, Revenues, Share Prices
I found the production cost estimate of $0.60 per dose (per day) most interesting. Makes sense. Anavex 2-73 is not a monoclonal antibody (MAB). MABs are extremely costly to produce. https://www.moleculardevices.com/monoclonal-a...production
Anavex 2-73 is a rather complex organic molecule (tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride), but production of a dose at 60 cents is feasible. A dose is probably 30 to 60 milligrams. A single pound of synthesized Anavex 2-73 would make 7,559 60mg pills, enough to treat 20 people for a year.
From all of this, the question of how much Anavex Life Sciences Corp will charge for a day’s dosage of Anavex 2-73 arises. For my punch-the-numbers projections, I’ve (conservatively) punched in about $3 per day pill cost, which is $1095 of annual income per treated patient.
Do your own projections of future annual Anavex Life Sciences Corp revenues. List the number of central nervous system diseases Anavex 2-73 will treat. Then try to determine the general size ranges of populations with those diseases that will be treated. Count all the many zeros that start appearing after the dollar sign.
Then, go on out several more years, when a) other diseases and conditions will be treated, and b) when Anavex 3-71 attains market status, treating even more diseases, more effectively.
Lastly (with the biggest numbers of all) punch the numbers if it is discovered (as I think it will be) that Anavex drugs not only treat existing diseases and conditions, but actually prevent them and significantly delay geriatric decline in humans (the anti-aging factor).
Presently, there are 49.12 million AVXL shares outstanding, in circulation. Will that quantity remain? Punch in various share counts; against anticipated corporate revenues. From those projections, share prices can be hazily estimated. All of my share-price projections require at least three digits; some, four, especially farther out.
Private Reply | Keep | Public Reply | View Replies (1) | Mark as Last Read
https://investorshub.advfn.com/boards/read_pe...;nummsgs=1
Fletch
falconer66a Tuesday, 05/14/19 01:26:51 PM
Re: Bourbon_on_my_cornflakes post# 192761 0
Post # of 192830
Production Cost, Revenues, Share Prices
I found the production cost estimate of $0.60 per dose (per day) most interesting. Makes sense. Anavex 2-73 is not a monoclonal antibody (MAB). MABs are extremely costly to produce. https://www.moleculardevices.com/monoclonal-a...production
Anavex 2-73 is a rather complex organic molecule (tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride), but production of a dose at 60 cents is feasible. A dose is probably 30 to 60 milligrams. A single pound of synthesized Anavex 2-73 would make 7,559 60mg pills, enough to treat 20 people for a year.
From all of this, the question of how much Anavex Life Sciences Corp will charge for a day’s dosage of Anavex 2-73 arises. For my punch-the-numbers projections, I’ve (conservatively) punched in about $3 per day pill cost, which is $1095 of annual income per treated patient.
Do your own projections of future annual Anavex Life Sciences Corp revenues. List the number of central nervous system diseases Anavex 2-73 will treat. Then try to determine the general size ranges of populations with those diseases that will be treated. Count all the many zeros that start appearing after the dollar sign.
Then, go on out several more years, when a) other diseases and conditions will be treated, and b) when Anavex 3-71 attains market status, treating even more diseases, more effectively.
Lastly (with the biggest numbers of all) punch the numbers if it is discovered (as I think it will be) that Anavex drugs not only treat existing diseases and conditions, but actually prevent them and significantly delay geriatric decline in humans (the anti-aging factor).
Presently, there are 49.12 million AVXL shares outstanding, in circulation. Will that quantity remain? Punch in various share counts; against anticipated corporate revenues. From those projections, share prices can be hazily estimated. All of my share-price projections require at least three digits; some, four, especially farther out.
Private Reply | Keep | Public Reply | View Replies (1) | Mark as Last Read
https://investorshub.advfn.com/boards/read_pe...;nummsgs=1
(1)
(0)